Phase 2 Trials – Talk Bio

Sanofi Acquires Vigil Neuroscience for $470 Million, Bolstering Alzheimer’s Drug Pipeline

2 weeks ago talkbio0Tagged Acquisition, Agonist, Alzheimer 's disease, Microglia, Neurodegenerative Disorders, Phase 2 Trials, sanofi, TREM2, VG-3927, Vigil Neuroscience

Sanofi; Vigil Neuroscience; acquisition; Alzheimer’s disease; TREM2 agonist; VG-3927; microglia; neurodegenerative disease; Phase 2 trials; biotech deals

AstraZeneca’s IL-33 Drug Shows Mixed Results in COPD Trials, Despite Phase 2 Setbacks

9 months ago talkbio0Tagged AstraZeneca, Chronic Obstructive Airway Disease, IL33 protein, human, Phase 2 Trials, Respiration Disorders, Tozorakimab

AstraZeneca, IL-33, COPD, tozorakimab, phase 2 trials, respiratory diseases

Pfizer and Valneva Report Strong Immune Responses from Second Lyme Disease Vaccine Booster

9 months ago talkbio0Tagged Immune response, Lyme Disease, Pfizer, Phase 2 Trials, Submission, United States Food and Drug Administration, Vaccines, Valneva, VLA15

Lyme disease, vaccine, Pfizer, Valneva, VLA15, booster, immune response, Phase 2 trials, FDA submission

Neurocrine-Takeda Collaboration Shows Promise in Alleviating Depression Symptoms in Phase 2 Trials

1 year ago talkbio0Tagged Mental Depression, Neurocrine, Phase 2 Trials, Severities, Takeda

Neurocrine, Takeda, Phase 2 trials, depression, depression severity, medication, analysts, data detail.